Following a directed appraisal
AWMSG advice |
|||
| Status: Recommended | |||
Miglustat is recommended as an option for use within NHS Wales for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. |
|||
|
|||
Medicine details |
|||
| Medicine name | miglustat | ||
| Formulation | 100 mg capsule | ||
| Reference number | 371 | ||
| Indication | For the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease |
||
| Company | Generic medicine | ||
| BNF chapter | Nutrition & blood | ||
| Submission type | Directed | ||
| Status | Recommended | ||
| Advice number | 0624 | ||
| AWMSG meeting date | 08/10/2024 | ||
| Date of issue | 09/10/2024 | ||